Neutrophil Gelatinase-associated Lipocalin as a Predictor of Acute Kidney Injury in Patients during Treatment with Colistimethate Sodium
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: The emergence of multidrug-resistant, Gram-negative bacteria has resulted in reconsideration of colistimethate sodium (CMS) as a last resort for treatment of such infections. However, acute kidney injury (AKI) may represent a major limiting adverse effect of use of CMS. Early AKI detection in CMS-treated patients can help prevent progression to acute failure and reduce the need of renal replacement therapy. We hypothesized that plasma neutrophil gelatinase-associated lipocalin (NGAL) may be an early biomarker of AKI in CMS-treated patients. Materials and Methods: This prospective cohort study included patients aged ≥20 years who received intravenous CMS between March 2014 and November 2015. AKI was defined according to Kidney Disease: Improving Global Outcomes criteria. The primary endpoint was the difference between the average time to AKI onset based on serum creatinine and empirically derived plasma NGAL levels. Results: Among 109 CMS-treated patients, 23 patients (mean age, 61.3 ± 16.1 years; men, 65.2%) were evaluated. Thirteen (56.5%) patients fulfilled the AKI criteria. The mean time to AKI onset based on serum creatinine after CMS initiation was 78.15 ± 30.49 hours. AKI was detected approximately 22 hours earlier using plasma NGAL than when using serum creatinine as an indicator of AKI (P = 0.035). The baseline plasma NGAL level was 264.0 ± 167.3 ng/mL and 192.7 ± 65.3 ng/mL in patients with and without AKI, respectively (P = 0.218). The area under the curve for plasma NGAL level at 56 hours was 0.796 (95% confidence interval, 0.609–0.983; P = 0.017), with a sensitivity and specificity of 69.2% and 90.0%, respectively (cutoff value, 285 ng/mL). Conclusion: NGAL level was found to be a strong predictor of AKI. This study provides additional evidence of the utility of NGAL for AKI in patients with treated CMS. Plasma NGAL represent sensitive and specific predictive early biomarkers for AKI in patient treated CMS.
Abstract
Background: The emergence of multidrug-resistant, Gram-negative bacteria has resulted in reconsideration of colistimethate sodium (CMS) as a last resort for treatment of such infections. However, acute kidney injury (AKI) may represent a major limiting adverse effect of use of CMS. Early AKI detection in CMS-treated patients can help prevent progression to acute failure and reduce the need of renal replacement therapy. We hypothesized that plasma neutrophil gelatinase-associated lipocalin (NGAL) may be an early biomarker of AKI in CMS-treated patients. Materials and Methods: This prospective cohort study included patients aged ≥20 years who received intravenous CMS between March 2014 and November 2015. AKI was defined according to Kidney Disease: Improving Global Outcomes criteria. The primary endpoint was the difference between the average time to AKI onset based on serum creatinine and empirically derived plasma NGAL levels. Results: Among 109 CMS-treated patients, 23 patients (mean age, 61.3 ± 16.1 years; men, 65.2%) were evaluated. Thirteen (56.5%) patients fulfilled the AKI criteria. The mean time to AKI onset based on serum creatinine after CMS initiation was 78.15 ± 30.49 hours. AKI was detected approximately 22 hours earlier using plasma NGAL than when using serum creatinine as an indicator of AKI (P = 0.035). The baseline plasma NGAL level was 264.0 ± 167.3 ng/mL and 192.7 ± 65.3 ng/mL in patients with and without AKI, respectively (P = 0.218). The area under the curve for plasma NGAL level at 56 hours was 0.796 (95% confidence interval, 0.609–0.983; P = 0.017), with a sensitivity and specificity of 69.2% and 90.0%, respectively (cutoff value, 285 ng/mL). Conclusion: NGAL level was found to be a strong predictor of AKI. This study provides additional evidence of the utility of NGAL for AKI in patients with treated CMS. Plasma NGAL represent sensitive and specific predictive early biomarkers for AKI in patient treated CMS.
참고문헌 (33)
- Wareham DW, "Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multidrug resistance", Eur J Clin Microbiol Infect Dis, 27, pp.607~612 (2008)[DOI]
- Li J, "Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections", Lancet Infect Dis, 6, pp.589~601 (2006)[DOI]
- Falagas ME, "Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections", Clin Infect Dis, 40, pp.1333~1341 (2005)[DOI]
- Ko HJ, "Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin", Nephron Clin Pract, 117, pp.c284~c288 (2011)[DOI]
- Kwon JA, "Predictors of acute kidney injury associated with intravenous colistin treatment", Int J Antimicrob Agents, 35, pp.473~477 (2010)[DOI]
- Falagas ME, "Toxicity of polymyxins: a systematic review of the evidence from old and recent studies", Crit Care, 10, pp.R27~ (2006)[DOI]
- Ricci Z, "The RIFLE criteria and mortality in acute kidney injury: a systematic review", Kidney Int, 73, pp.538~546 (2008)[DOI]
- Schrier RW, "Early intervention in acute kidney injury", Nat Rev Nephrol, 6, pp.56~59 (2010)[DOI]
- Bellomo R, "Defining acute renal failure: physiological principles", Intensive Care Med, 30, pp.33~37 (2004)[DOI]
- Chiou WL, "Pharmacokinetics of creatinine in man and its implications in the monitoring of renal function and in dosage regimen modifications in patients with renal insufficiency", J Clin Pharmacol, 15, pp.427~434 (1975)[DOI]
- McCullough PA, "Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference", Contrib Nephrol, 182, pp.13~29 (2013)
- Haase M, "Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis", Am J Kidney Dis, 54, pp.1012~1024 (2009)[DOI]
- Mishra J, "Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery", Lancet, 365, pp.1231~1238 (2005)[DOI]
- Gaspari F, "Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study", Nephron Clin Pract, 115, pp.c154~c160 (2010)[DOI]
- Shapiro NI, "The diagnostic accuracy of plasma neutrophil gelatinase-associated lipocalin in the prediction of acute kidney injury in emergency department patients with suspected sepsis", Ann Emerg Med, 56, pp.52~59 (2010)[DOI]
- Sen S, "Whole blood neutrophil gelatinase-associated lipocalin predicts acute kidney injury in burn patients", J Surg Res, 196, pp.382~387 (2015)[DOI]
- Garonzik SM, "Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients", Antimicrob Agents Chemother, 55, pp.3284~3294 (2011)[DOI]
- Cruz DN, "Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population", Intensive Care Med, 36, pp.444~451 (2010)[DOI]
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation", J Chronic Dis, 40, pp.373~383 (1987)[DOI]
- Khwaja A, "KDIGO clinical practice guidelines for acute kidney injury", Nephron Clin Pract, 120, pp.179~184 (2012)
- Vanmassenhove J, "Influence of severity of illness on neutrophil gelatinase-associated lipocalin performance as a marker of acute kidney injury: a prospective cohort study of patients with sepsis", BMC Nephrol, 16, pp.18~ (2015)[DOI]
- Hartzell JD, "Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center", Clin Infect Dis, 48, pp.1724~1728 (2009)[DOI]
- Cowland JB, "Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans", Genomics, 45, pp.17~23 (1997)[DOI]
- Park HD, "The relationship between serum neutrophil gelatinase-associated lipocalin and renal function in patients with vancomycin treatment", Ann Clin Lab Sci, 42, pp.7~13 (2012)
- Wang M, "Diagnostic and prognostic value of neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinases-1 for sepsis in the Emergency Department: an observational study", Crit Care, 18, pp.634~ (2014)[DOI]
- Makris K, "Evaluation of a particle enhanced turbidimetric assay for the measurement of neutrophil gelatinase-associated lipocalin in plasma and urine on Architect-8000: Analytical performance and establishment of reference values", Clin Biochem, 48, pp.1291~1297 (2015)[DOI]
- Katagiri D, "New biomarker panel of plasma neutrophil gelatinase-associated lipocalin and endotoxin activity assay for detecting sepsis in acute kidney injury", J Crit Care, 28, pp.564~570 (2013)[DOI]
- Axelsson L, "Studies of the release and turnover of a human neutrophil lipocalin", Scand J Clin Lab Invest, 55, pp.577~588 (1995)[DOI]
- Schley G, "Comparison of plasma and urine biomarker performance in acute kidney injury", PLoS One, 10, pp.e0145042~ (2015)[DOI]
- Kumpers P, "Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury", Crit Care, 14, pp.R9~ (2010)[DOI]
- Kim S, "Is plasma neutrophil gelatinase-associated lipocalin a predictive biomarker for acute kidney injury in sepsis patients? A systematic review and meta-analysis", J Crit Care, 33, pp.213~223 (2016)[DOI]
- Shavit L, "Urinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistin", Clin Nephrol, 80, pp.405~416 (2013)[DOI]
- Rocha PN, "Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury", Antimicrob Agents Chemother, 59, pp.6913~6921 (2015)[DOI]